Science + MATRIX Discovery

Decoding the electrical
language of biology.

MATRIX Discovery is Electrome's operating internal AI-native R&D software.

+−+−+−+−+−+−+−+−+−+−+−+−+−+−+−+−+−+−
Bioelectric signaling between cells

Specialized tools help scientists ground questions in evidence, compare hypotheses, rank candidate waveforms, model signals, design controlled experiments, and validate results. AI supports the work; people own the scientific decisions and every release gate.

Bioelectric mechanismPeer-reviewed27.12 MHz PSWTTranslational science
Discovery

Cells communicate with electrical signals.

Every cell in the human body communicates through electrical signals. From pain perception and inflammation to tissue repair and neurological activity, bioelectric signaling helps coordinate many of the body's most fundamental biological processes.

Electrome's platform is designed to study, model, and therapeutically influence these signaling systems using precisely engineered electromagnetic therapies and AI guided signal discovery.

Why It Matters

Bioelectric medicine represents one of the most underexplored frontiers in modern therapeutics.

Why Now

Medicine knows chemistry well. Bioelectric signaling is less understood.

Advances in electrophysiology, computational biology, AI modeling, miniaturized electronics, and real world clinical data are enabling a new generation of programmable bioelectric therapeutics.

Electrome is helping advance a complementary approach centered on the electrical behavior of biological systems. What was once difficult to observe is becoming measurable.

The Electrome Stack

An operating system for bioelectric therapeutics.

Programmable medicine for the electrical era of biology, built layer by layer.

LAYER 01
Biology
Cells, tissue, neural networks, immune signaling.
LAYER 02
Electrical Activity
Membrane potentials, ion flux, oscillatory signaling.
LAYER 03
AI Intelligence
Signal discovery, modeling, pattern recognition.
LAYER 04
Research Applications
Pain research and exploratory work in recovery, neurology, oncology, and infection. Not cleared uses for one device.
Therapeutic Domains

One platform. A growing pipeline of programmable signals.

Pain and recovery anchor commercial entry. AI signal discovery extends the platform across biological systems.

FDA Cleared

Pain & Inflammation

ActiPatch® uses pulsed shortwave therapy (PSWT) and is FDA cleared for adjunctive treatment of musculoskeletal pain. Its clearance does not establish tissue healing or disease treatment. Research into other bioelectric applications is separate from this labeled use.

Research focus areas
  • FDA-cleared therapy foundation
  • Drug-free adjunctive pain relief
  • over-the-counter (OTC) and clinical deployment
  • Device-specific indications
Active Research

Tissue Healing & Recovery

Bioelectric signaling is studied in tissue repair, circulation, and cellular responses. Electrome is exploring these mechanisms as research directions. This work does not establish a cleared healing indication for ActiPatch® or an available tissue-regeneration therapy.

Research focus areas
  • Recovery focused applications
  • Post operative support
  • Rehabilitation workflows
  • Inflammation modulation
Exploration

Infection & Immunology

Emerging research suggests bioelectric signaling may influence immune behavior, inflammation, cellular defense mechanisms, and microbial environments. Electrome is exploring how programmable electromagnetic therapies could contribute to future anti infective and immunomodulatory applications.

Research focus areas
  • Immune signaling research
  • Inflammatory pathway modulation
  • Host environment interaction
  • Future programmable therapies
Exploration

Cancer & Cellular Signaling

Membrane potentials and cellular communication are studied in cancer biology. Electrome is exploring these mechanisms; this is not an oncology treatment, a clinical outcome claim, or an ActiPatch® indication.

Research focus areas
  • Cellular signaling research
  • Tumor microenvironment exploration
  • AI guided discovery platform
  • Future therapeutic applications
Exploration

Brain Health & Neurotechnology

The brain relies on coordinated electrical activity. Electrome is exploring neural signaling as a research direction, not offering a cognitive-wellness or neurological treatment. Clinical benefit and safety would require independent study.

Research focus areas
  • Neural signaling
  • Cognitive wellness
  • Bioelectric interfaces
  • Neuroregulation research
Exploration

Bioelectric Ocular Therapeutics

Retinal signaling and visual-system responses are research interests for Electrome. Programmable electromagnetic approaches remain exploratory, with no established clinical benefit or available Electrome ocular therapy.

Research focus areas
  • Retinal signaling modulation
  • Neuroinflammatory pathway targeting
  • AI-assisted ophthalmic signal discovery
  • Non-invasive therapeutic delivery
FDA Cleared

ActiPatch®: Bioelectric pain management platform

ActiPatch® is a drug-free wearable pulsed shortwave therapy (PSWT) device, FDA cleared for adjunctive treatment of musculoskeletal pain. Use it alongside other treatments as directed. Clinical studies report pain outcomes, not proof of disease treatment. Individual results vary. For a practical consumer overview, compare ActiPatch® with common pain relief options.

FDA ClearedUp to 720 hrs continuousDrug-freeWearable, non invasive
ActiPatch bioelectric loop

Standard loop: 12 cm (4.7 inches) in diameter.

How We Work

Four commitments behind the science.

AI organizes the evidence, scientists review every gate, products stay within their FDA clearances, and research reaches people through established channels.

AI
Native discovery orchestration
Human
Scientific review at every gate
FDA
Cleared therapeutic foundation
Multi
Channel commercialization
Platform Flywheel

A research feedback loop, not automatic device telemetry.

Properly authorized studies and manually collected outcomes may inform future research. ActiPatch® does not transmit patient data, pair with an app, or adapt its output. The diagram describes a research direction, not a connected clinical service. The full human-led workflow and its maturity map live on the Platform page.

See the research workflow
Step 01
Therapy Deployment
Step 02
Clinical Data
Step 03
Signal Intelligence
Step 04
AI Optimization
Step 05
Therapeutic Discovery
Step 06
Expanded Applications
The Long Arc of Medicine

Medicine evolvedin waves.

  1. Era I
    Chemistry
  2. Era II
    Biologics
  3. Era III
    Genomics
  4. Era IV
    AI
  5. Era V
    Bioelectric Medicine

The next era of medicine will be programmable.

This is a historical framing, not a product claim. For what exists today and what remains future research, see the Vision horizons.

Research Pulse

Live from PubMed and FDA 510(k)

Loading research feed…
Research areas

Where bioelectric signaling research is going.

Electrome's broader ecosystem includes commercial programs, pipeline initiatives, and exploratory research. These initiatives sit at varying stages of commercialization, pipeline development, and computational modeling. No efficacy claims are made regarding exploratory research programs.

This page is provided for scientific and informational purposes only. References to published studies, exploratory research, or FDA cleared technologies should not be interpreted as generalized efficacy claims. Statements regarding future applications, computational systems, and exploratory research initiatives are forward-looking and subject to scientific, clinical, and regulatory uncertainty.

Preclinical publication proof point

A Discovery R&D loop that reached peer review.

A platform-selected candidate produced a measurable, replicated in-vitro result on the first day of experiments; peer-reviewed publication followed approximately six months after the initial laboratory work.

Frontiers in Medicine · August 11, 2026Preclinical · In vitro · Research only

Arresting spirochetes: nonthermal extremely low-frequency electromagnetic field exposure suppresses Borrelia burgdorferi motility in vitro

Erik A. Nilsen, Heather Adkison, John R. Martinez, Nevena Zubcevik, and Monica E. Embers

This preclinical in-vitro result does not establish a Lyme disease treatment, cure, clinical efficacy, or use in people. No Electrome product is cleared or marketed for Lyme disease or any infectious condition.

Read the canonical research record

The future of precision medicine is bioelectric.

Electrome is building the infrastructure, therapies, and intelligence systems designed to help unlock the next frontier of programmable biology.

Appearance